Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346

Antibe Therapeutics (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the secondary endpoint data from the recent Phase 2B gastrointestinal safety study for its lead drug, ATB-346. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the United States.

As quoted in the press release:

Antibe announced the successful completion of this study on March 20, 2018 with strong primary endpoint data. The primary endpoint for the study was the incidence of gastric or duodenal ulcers of at least 3 mm diameter with unequivocal depth, considered the gold standard in assessing the GI safety of NSAIDs. As previously reported, subjects on ATB-346 exhibited an ulceration rate of 2.5% versus an ulceration rate of 42.1% for subjects on naproxen at the end of the 2-week treatment period. These results exhibited a very high degree of statistical significance (p<0.0001). ATB-346 was also safe and well tolerated.

Click here to read the full press release.